Eylea (aflibercept): J0178 billing, dosing and coverage

Eylea and the anti-VEGF family

9 HCPCS codes, one target: Eylea is one of nine anti-VEGF products used for retinal disease, each priced and billed under its own code. They are not interchangeable, and most commercial policies write a preferred product into the claim before Eylea is approved. Pricing comparison lives in Current Eylea pricing.

What Eylea is billed for

Eylea carries five labeled indications, each with its own ICD-10 code: neovascular (wet) age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, diabetic retinopathy, and retinopathy of prematurity. Full dosing by indication is in Eylea dosing by indication below, and the claim structure is in Eylea billing reference.

22 of 28 aflibercept payer policies in the corpus require a preferred agent first, usually repackaged bevacizumab (Avastin, off-label, J9035). BCBS AR instead lists Byooviz, Lucentis, Pavblu and Vabysmo as its preferred products, ahead of Eylea itself: “Initial request must be for a preferred product. If initial request is not a preferred product, an administrative denial will be issued.”

Eylea HD (J0177)

Regeneron · aflibercept 8 mg. A separate FDA approval with its own J-code and its own dosing; it is not interchangeable with the 2 mg Eylea (J0178) dose on a claim.

Pavblu (Q5147)

Amgen · aflibercept-ayyh, the FDA-approved aflibercept biosimilar. Several payers, including BCBS AR, list Pavblu as preferred over Eylea itself; check the specific policy before assuming Eylea is first-line.

Eylea dosing by indication

Every adult indication is the same 2 mg (0.05 mL) intravitreal injection; what changes is the loading schedule and how soon the interval opens up to every 8 weeks. Retinopathy of prematurity, the pediatric indication, uses a smaller 0.4 mg dose.

Schedule by indication

Wet AMD: 2 mg every 4 weeks for the first 3 months, then 2 mg every 8 weeks (some patients need every-4-week dosing beyond that). Macular edema following RVO: 2 mg every 4 weeks, with no step-down to a longer interval on the label.

Diabetic macular edema and diabetic retinopathy: 2 mg every 4 weeks for the first 5 doses, then 2 mg every 8 weeks. Retinopathy of prematurity, the pediatric indication: 0.4 mg (0.01 mL) per eye, repeated no sooner than 10 days later if needed.

A 0.4 mg ROP dose still rounds up to 1 unit of J0178; drawn from the same 2 mg single-dose vial, the remaining 1.6 mg is discarded and reported on a JW line — 2 units drawn, 1 unit administered.

Contraindications and warnings

Eylea carries no boxed warning. Contraindications are ocular or periocular infection, active intraocular inflammation, and known hypersensitivity to aflibercept or any excipient. The label also warns of endophthalmitis and retinal detachment associated with intravitreal injections; document the dose, the eye treated, and any post-injection symptoms in the chart at every visit.

Duration

Treatment is open-ended: the label sets no stopping point, and the maintenance interval is individualized on OCT imaging and visual acuity, which is why commercial policies reauthorize on documented response rather than on a calendar. Two eyes are two separate treatment courses, each with its own laterality on the claim.

Need the billing units for a patient? Convert dose to J0178 billing units →

Eylea billing reference

HCPCS

J0178: 1 mg per billing unit. A 2 mg dose bills as 2 units; billing units are always whole numbers even though the dose itself is measured in mg.

NDC

Two packages, each its own NDC: 61755-005-02 (single-dose vial kit) and 61755-005-55 (single-dose prefilled syringe). Pad to 11 digits with a leading zero in the appropriate segment for CMS-1500 Box 24A.

Administration: 67028 per eye, never 96372

The injection is the procedure, and it is reported per eye, because Eylea has no administration code of its own. 96372 is wrong on every intravitreal claim.

A complete one-eye claim has two lines: J0178 × 2 units with JZ and the eye modifier, and 67028 with the same eye modifier. A bilateral visit adds a second drug line for the other eye and reports the injection once, as 67028-50, rather than two separate 67028 lines.

The Medically Unlikely Edit for J0178 is 4 units a day — two eyes at 2 units each — which is the practical ceiling for a same-day bilateral claim, not a sign of an error.

Modifiers

JZ: required on every standard Eylea dose line, since the full single-dose vial or prefilled syringe is administered. JW: applies only to the pediatric ROP dose, where 1.6 mg of the 2 mg vial goes unused. RT / LT / 50: required on both the drug line and the 67028 line.

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded, and JW whenever any is. Document the discarded amount in the chart and bill the JW line on a separate claim line, same date of service, same HCPCS code; never both modifiers on the same line.

Modifier 25: same-day E/M. Append modifier 25 to the same-day E/M code only if a significant, separately identifiable evaluation occurred beyond the routine pre-injection check-in, which is bundled into the procedure code.

TB: 340B drug pricing. Hospitals that acquire aflibercept through 340B and bill Medicare report the TB modifier, the sole 340B identifier since CMS discontinued JG on January 1, 2025.

Claim form

CMS-1500 / 837P (physician office; POS 11) field map for a J0178 claim.

Calculate units & the eye modifier →

Eylea coverage

• 24 of 28 commercial payer policy sets require prior authorization; 4 do not say clearly, so confirm those on the call
• 7 name a preferred aflibercept product
• 28 payers carry an aflibercept policy, covering 388 individual rules across covered indications, clinical prerequisites, quantity limits, contraindication exclusions, reauthorization, prior authorization, dosing, step therapy, preferred product, site of care, and combination rules
• 22 of 28 payers require another product first, most often repackaged bevacizumab (Avastin), though several instead name a ranibizumab product or the aflibercept biosimilar Pavblu as preferred
• 24 rules set a per-indication quantity limit, and 4 more set reauthorization terms that require continued-response documentation to keep the claim approved
• Because Eylea, Eylea HD and Pavblu are three separate HCPCS codes for three distinct products, confirm which code the policy actually names before treating; Eylea HD is not interchangeable with Eylea on the claim

ICD-10 codes by indication

Use the most specific code supported by chart documentation. Each labeled indication has its own code.

Step therapy: a preferred agent first

22 of 28 aflibercept payer policies in the corpus require a preferred agent before Eylea, most often repackaged bevacizumab. BCBS KS: “Patient must have a contraindication, intolerance, or failure to a bevacizumab product prior to the consideration of another ophthalmic VEGF-inhibitor product.” BCBS MI: “Treatment with bevacizumab or a bevacizumab biosimilar has been ineffective, not tolerated or contraindicated.” BCBS MI waives that step for diabetic macular edema when visual acuity in the affected eye is 20/50 or worse, and for retinopathy of prematurity. Anthem: “Individual has had a trial and inadequate response or intolerance to one preferred agent.” BCBS MS instead names ranibizumab as the preferred step: “Treatment with ranibizumab or a ranibizumab biosimilar has been ineffective, not tolerated, or contraindicated.”

Preferred over Eylea itself

Some payers rank Eylea below a competing product. BCBS AR: “Initial request must be for a preferred product. If initial request is not a preferred product, an administrative denial will be issued,” naming Byooviz, Lucentis, Pavblu and Vabysmo as its preferred products ahead of Eylea.

Quantity limits

Several payers cap the annual dose count on top of the label's own interval. UHC: “Intravitreal VEGF or dual VEGF/Ang-2 inhibitor administration is no more than 12 doses per year per eye, regardless of diagnosis.” BCBS MI aligns its limit to labeled dosing directly and authorizes for 60 days up to a year at a time; Wellmark's initial approval runs 6 months before reauthorization is required.

Reauthorization

Coverage is not open-ended once approved. Reauthorization runs on documented clinical response — stable or improved best corrected visual acuity and OCT anatomy — rather than a fixed calendar; BCBS KS and Capital Blue both renew authorization on a 12-month cycle when that response is documented.

Medicare carries no National Coverage Determination for intravitreal anti-VEGF drugs; coverage runs through your MAC's Local Coverage Determination. See Medicare covered diagnoses for Eylea for the MAC-level detail.

Check the patient's actual policy: See Eylea coverage by payer →

Current Eylea pricing

Medicare ASP+6%: $722.251 / 1 mg · $1,444.50 / 2 mg. For a one-eye claim, the drug line prices at 2 mg × $722.251 = $1,444.50; add the $114.23 non-facility PFS allowance for 67028, and the claim totals $1,558.73 before the sequester, with a Medicare 20% coinsurance share of $311.75.

Both eyes at the same visit price at $3,060.35 allowed ($612.07 at 20%), with 67028-50 replacing the two separate procedure lines. Commercial rates run higher: Aetna's all-payer median is $916 per mg, pricing a 2 mg dose at $1,832.00, and 37 of 37 payer files in the corpus carry a J0178 rate.

Sequestration reduces Medicare's 80% share by 2%. Commercial plans pay a contracted rate that differs by payer and state.

7 doses a year (2 mg per eye, three monthly doses then every 8 weeks) at $1,558.73 per dose — drug plus 67028 administration — total $10,911.12 before the sequester. That is the full annual drug-plus-administration cost for a patient staying on schedule, before benefits or assistance.

Look up commercial reimbursement →

Patient cost

The patient's actual responsibility depends on: payer allowed rate · remaining Part B deductible ($283 in 2026) · benefits · − assistance · = patient responsibility. At 20% coinsurance with the deductible already met, a Medicare patient's share of a one-eye Eylea visit is $311.75: $288.90 on the drug line, $22.85 on the 67028 procedure line. Both eyes at the same visit run $612.07: $288.90 per eye on the drug lines plus $34.27 on the 67028-50 line.

Calculate an Eylea patient estimate →

Copay & financial assistance

Two Regeneron programs cover Eylea: EYLEA4U Copay Card lets commercial patients pay as little as $0 per treatment for the drug, up to $20,000 a year, plus up to $1,000 a year toward administration (not in MA or RI); Regeneron Patient Assistance provides the drug free to qualifying uninsured patients, patients whose coverage falls short and some Medicare patients who meet the program's rules, (no income limit is published; call the program to check). The copay card excludes Medicare, Medicaid and other government insurance. Regeneron Patient Assistance can accept underinsured patients, and Medicare patients who show financial need. Check current open/closed status before pointing a patient to either, since status changes without notice.

Nine foundation funds are on file for Eylea. The Assistance Fund's Macular Degeneration fund is on file; check each fund's current status on the funds list. The other eight are HealthWell Foundation's Macular Degeneration fund (up to $4,000 a year), Good Days' two retinal-disease funds, and five TotalAssist eye funds; check each fund's current status on the funds list. See current Eylea assistance programs →

See current Eylea assistance programs →

Common Eylea denials & fixes